Cognition Therapeutics Nasdaq/NYSE Compliance Notice
Cognition Therapeutics received a deficiency notice from Nasdaq on November 3, 2026, because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
- Counterparty
- Nasdaq
- Term
- 180 days
“The work we conducted with the Office of Neuroscience at the FDA during 2026 culminated in the development of a trial protocol for a planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB). We are now evaluating our plans for manufacturing, site selection, and patient recruitment.”
Lisa Ricciardi, Cognition’s president and CEO
“At the same time, we are working with our collaborators at the Alzheimer’s Clinical Trial Consortium (ACTC) to prepare for the conclusion of the Phase 2 START Study in people with MCI and early Alzheimer’s disease. Top-line results from START are anticipated in the second half of 2027 and will inform our plans for zervimesine in Alzheimer’s disease.”
Lisa Ricciardi, Cognition’s president and CEO